Intellia Therapeutics Files 8-K
Ticker: NTLA · Form: 8-K · Filed: Nov 18, 2024 · CIK: 1652130
Sentiment: neutral
Topics: disclosure, corporate-events
TL;DR
Intellia Therapeutics filed an 8-K on Nov 18th for events on Nov 16th. Standard disclosure.
AI Summary
Intellia Therapeutics, Inc. filed an 8-K on November 18, 2024, reporting on events that occurred on November 16, 2024. The filing is categorized under Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The company is incorporated in Delaware and its principal executive offices are located in Cambridge, Massachusetts.
Why It Matters
This 8-K filing provides an update on Intellia Therapeutics' corporate activities and disclosures, which could be relevant for investors monitoring the company's regulatory compliance and operational events.
Risk Assessment
Risk Level: low — This filing appears to be a routine corporate disclosure and does not immediately indicate significant new risks or material adverse events.
Key Players & Entities
- Intellia Therapeutics, Inc. (company) — Registrant
- November 16, 2024 (date) — Earliest event reported
- November 18, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- Cambridge, Massachusetts (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing for Intellia Therapeutics, Inc.?
The primary purpose is to report on events that occurred on November 16, 2024, under categories including Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.
When was this 8-K filing submitted to the SEC?
The filing was submitted on November 18, 2024.
Where are Intellia Therapeutics, Inc.'s principal executive offices located?
The principal executive offices are located at 40 Erie Street, Suite 130, Cambridge, Massachusetts, 02139.
What is the state of incorporation for Intellia Therapeutics, Inc.?
Intellia Therapeutics, Inc. is incorporated in Delaware.
What is the SEC file number for Intellia Therapeutics, Inc.?
The SEC file number is 001-37766.
Filing Stats: 1,799 words · 7 min read · ~6 pages · Grade level 13.1 · Accepted 2024-11-18 07:00:32
Key Financial Figures
- $0.0001 — ich registered Common Stock (Par Value $0.0001) NTLA The Nasdaq Global Market Ind
Filing Documents
- d828128d8k.htm (8-K) — 44KB
- d828128dex991.htm (EX-99.1) — 36KB
- g828128g25z80.jpg (GRAPHIC) — 23KB
- g828128g60q26.jpg (GRAPHIC) — 14KB
- 0001193125-24-260417.txt ( ) — 266KB
- ntla-20241116.xsd (EX-101.SCH) — 3KB
- ntla-20241116_lab.xml (EX-101.LAB) — 18KB
- ntla-20241116_pre.xml (EX-101.PRE) — 11KB
- d828128d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K and certain of the materials furnished or filed herewith contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia's beliefs and expectations regarding: the safety, efficacy, success and advancement of its clinical programs for nexiguran ziclumeran or "nex-z" (also known as NTLA-2001), for transthyretin ("ATTR") amyloidosis, including the ability to successfully complete our global Phase 3 MAGNITUDE study for ATTR amyloidosis with cardiomyopathy ("ATTR-CM"), to initiate and complete our global Phase 3 MAGNITUDE-2 study for hereditary ATTR amyloidosis with polyneuropathy ("ATTRv-PN") pursuant to our clinical trial applications and investigational new drug submissions; and its belief in the success of its MAGNITUDE and MAGNITUDE-2 studies. Any forward-looking statements in this Current Report on Form 8-K are based on management's current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to Intellia's ability to protect and maintain its intellectual property position; risks related to valid third party intellectual property; risks related to Intellia's relationship with third parties, including its licensors and licensees; risks related to the abilit
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release dated November 16, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Intellia Therapeutics, Inc. Date: November 18, 2024 By: /s/ John M. Leonard Name: John M. Leonard Title: Chief Executive Officer and President